Discovery Labs Reports Encouraging Results for AEROSURF Phase 2a Clinical Program in Premature Infants 29-34 Weeks

Discovery Laboratories, Inc. DSCO today reported top line data from its recently completed AEROSURF® phase 2a clinical program in premature infants 29 to 34 week gestational age (GA) receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS).  The two-part program enrolled a total of 80 premature infants including 40 infants in five AEROSURF dose groups and 40 control infants on nCPAP alone.  The Company previously announced top line data from the initial trial in May 2015.  The Company is now reporting data on the overall phase 2a program in premature infants 29 to 34 week GA including the recently completed phase 2a expansion study.  The data are encouraging and suggest that aerosolized KL4 surfactant delivered to premature infants with RDS is generally safe and well tolerated and may decrease nCPAP failure and the need for intubation.  The Company is now advancing AEROSURF to a See full press release